Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
May 23, 2024 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and...
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
May 01, 2024 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo...
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
April 23, 2024 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions
April 04, 2024 09:04 ET
|
RapidPulse, Inc
Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
April 02, 2024 07:30 ET
|
Revive Therapeutics Ltd.
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
March 19, 2024 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study
February 28, 2024 07:00 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study....
Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep
February 05, 2024 04:00 ET
|
Blue California Ingredients
Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a...
NC AMVETS Service Foundation Launches CBD Study for Veterans with University of Northern Colorado and Vantage Hemp Co.
January 31, 2024 07:00 ET
|
NC AMVETS Service Foundation
Rockwell, North Carolina, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The North Carolina AMVETS Service Foundation, a 501(c)(3) extension of the state’s most inclusive congressionally chartered veterans...
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
January 04, 2024 07:00 ET
|
InflaRx N.V.
MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90%...